Predictive factors in localized prostate cancer

Implications for radiotherapy and clinical trial design

T. M. Pisansky, B. J. Davis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The anatomic extent of prostate cancer has long served the role of providing prognostic information to assist in therapeutic decision-making, evaluating treatment outcomes, facilitating information exchange between medical centers, and promoting cancer research. However, nonanatomic factors are also associated with important pathological features of this condition and may be used to estimate therapeutic outcome. At present, tumor grade (eg, Gleason score) ascertained from the diagnostic biopsy specimen and the pretherapy serum prostate-specific antigen level are readily available in clinical practice. This information may be used along with clinical tumor stage to construct predictive models. These models may provide reliable estimates for the likelihood of extraprostatic tumor extension, seminal vesicle invasion, or pelvic lymph-node involvement. Consideration of this information may play a vital role in the selection of radiotherapeutic modality and in the definition of external beam radiotherapy treatment volumes. These same factors are also associated with disease relapse and may be combined in a fashion to estimate the prospects for cancer control in the individual patient and in homogeneous patient groups. Grouping patients according to the risk for and site of disease recurrence may be instrumental in the development of clinical trials that assess therapeutic approaches in appropriate subsets of patients. (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)93-107
Number of pages15
JournalSeminars in Urologic Oncology
Volume18
Issue number2
StatePublished - 2000

Fingerprint

Prostatic Neoplasms
Radiotherapy
Clinical Trials
Neoplasms
Recurrence
Neoplasm Grading
Seminal Vesicles
Therapeutics
Prostate-Specific Antigen
Decision Making
Lymph Nodes
Biopsy
Serum
Research

Keywords

  • Lymph nodes
  • Prostate-specific antigen
  • Radiotherapy
  • Seminal vesicles

ASJC Scopus subject areas

  • Urology

Cite this

Predictive factors in localized prostate cancer : Implications for radiotherapy and clinical trial design. / Pisansky, T. M.; Davis, B. J.

In: Seminars in Urologic Oncology, Vol. 18, No. 2, 2000, p. 93-107.

Research output: Contribution to journalArticle

@article{25097f77bfbc440f86db2c8ac831b957,
title = "Predictive factors in localized prostate cancer: Implications for radiotherapy and clinical trial design",
abstract = "The anatomic extent of prostate cancer has long served the role of providing prognostic information to assist in therapeutic decision-making, evaluating treatment outcomes, facilitating information exchange between medical centers, and promoting cancer research. However, nonanatomic factors are also associated with important pathological features of this condition and may be used to estimate therapeutic outcome. At present, tumor grade (eg, Gleason score) ascertained from the diagnostic biopsy specimen and the pretherapy serum prostate-specific antigen level are readily available in clinical practice. This information may be used along with clinical tumor stage to construct predictive models. These models may provide reliable estimates for the likelihood of extraprostatic tumor extension, seminal vesicle invasion, or pelvic lymph-node involvement. Consideration of this information may play a vital role in the selection of radiotherapeutic modality and in the definition of external beam radiotherapy treatment volumes. These same factors are also associated with disease relapse and may be combined in a fashion to estimate the prospects for cancer control in the individual patient and in homogeneous patient groups. Grouping patients according to the risk for and site of disease recurrence may be instrumental in the development of clinical trials that assess therapeutic approaches in appropriate subsets of patients. (C) 2000 by W.B. Saunders Company.",
keywords = "Lymph nodes, Prostate-specific antigen, Radiotherapy, Seminal vesicles",
author = "Pisansky, {T. M.} and Davis, {B. J.}",
year = "2000",
language = "English (US)",
volume = "18",
pages = "93--107",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Predictive factors in localized prostate cancer

T2 - Implications for radiotherapy and clinical trial design

AU - Pisansky, T. M.

AU - Davis, B. J.

PY - 2000

Y1 - 2000

N2 - The anatomic extent of prostate cancer has long served the role of providing prognostic information to assist in therapeutic decision-making, evaluating treatment outcomes, facilitating information exchange between medical centers, and promoting cancer research. However, nonanatomic factors are also associated with important pathological features of this condition and may be used to estimate therapeutic outcome. At present, tumor grade (eg, Gleason score) ascertained from the diagnostic biopsy specimen and the pretherapy serum prostate-specific antigen level are readily available in clinical practice. This information may be used along with clinical tumor stage to construct predictive models. These models may provide reliable estimates for the likelihood of extraprostatic tumor extension, seminal vesicle invasion, or pelvic lymph-node involvement. Consideration of this information may play a vital role in the selection of radiotherapeutic modality and in the definition of external beam radiotherapy treatment volumes. These same factors are also associated with disease relapse and may be combined in a fashion to estimate the prospects for cancer control in the individual patient and in homogeneous patient groups. Grouping patients according to the risk for and site of disease recurrence may be instrumental in the development of clinical trials that assess therapeutic approaches in appropriate subsets of patients. (C) 2000 by W.B. Saunders Company.

AB - The anatomic extent of prostate cancer has long served the role of providing prognostic information to assist in therapeutic decision-making, evaluating treatment outcomes, facilitating information exchange between medical centers, and promoting cancer research. However, nonanatomic factors are also associated with important pathological features of this condition and may be used to estimate therapeutic outcome. At present, tumor grade (eg, Gleason score) ascertained from the diagnostic biopsy specimen and the pretherapy serum prostate-specific antigen level are readily available in clinical practice. This information may be used along with clinical tumor stage to construct predictive models. These models may provide reliable estimates for the likelihood of extraprostatic tumor extension, seminal vesicle invasion, or pelvic lymph-node involvement. Consideration of this information may play a vital role in the selection of radiotherapeutic modality and in the definition of external beam radiotherapy treatment volumes. These same factors are also associated with disease relapse and may be combined in a fashion to estimate the prospects for cancer control in the individual patient and in homogeneous patient groups. Grouping patients according to the risk for and site of disease recurrence may be instrumental in the development of clinical trials that assess therapeutic approaches in appropriate subsets of patients. (C) 2000 by W.B. Saunders Company.

KW - Lymph nodes

KW - Prostate-specific antigen

KW - Radiotherapy

KW - Seminal vesicles

UR - http://www.scopus.com/inward/record.url?scp=0034094453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034094453&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 93

EP - 107

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -